Imugene Limited Is A Clinical Stage Immuno Oncology Company Based In Sydneyaustraliafounded In 2012 And Publicly Traded On The Asximugene Focuses On Developing Innovative Immunotherapies That Activate The Immune Systems Of Cancer Patients Against Tumorsthe Company Entered The S&P Asx 200 Index In December 2021 Imugene Specializes In B Cell Immunotherapies And Oncolytic Virotherapiesaiming To Enhance Treatment Effectiveness Alongside Standard Therapies And Emerging Methods Like Car T Cell Therapyits Product Pipeline Includes Cf33 Vaxiniaa Chimeric Vaccinia Poxvirus For Advanced Solid Tumorsand Her Vaxxa B Cell Peptide Vaccine For Her 2 Neu Positive Cancersother Notable Products Include Pd1 Vaxxcheckvaccand Oncarlyticswhich Combines Oncolytic Viruses With Car T Cell Therapythe Company Employs Advanced Technologies Such As Mimotope Technology And Engineered Oncolytic Virotherapy To Stimulate Immune Responses And Target Cancer Cells
No conferences found for this company.
| Company Name | Imugene Ltd |
| Country |
Australia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
